MADISON, N.J., July 31 /PRNewswire-FirstCall/ -- On July 31, 2007, Wyeth will hold a conference call to provide an update on the Company’s plans for registration of Pristiq(TM) (desvenlafaxine succinate), a new drug being developed for both the treatment of vasomotor symptoms associated with menopause and the treatment of major depressive disorder. The conference call will begin at 5:00 p.m. Eastern time. Interested investors and others may listen to the call either in real time or on a delayed basis through our Internet webcast, which can be accessed by visiting our Web site at http://www.wyeth.com and clicking on the “Investor Relations” icon.
Wyeth is one of the world’s largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company’s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
The statements in this press release and on the related conference call that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In particular, the statements in this press release and on the related conference call regarding our expectations for Pristiq are based on a preliminary analysis of the FDA action letter received on July 23, 2007 regarding the vasomotor symptoms indication, subsequent discussions with the FDA, and our expectations as to the future regulatory approval process for the vasomotor symptoms and major depressive disorder indications, all of which are subject to risks and uncertainties. Risks and uncertainties include the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products (including Pristiq); government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; data generated on our products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption “Item 1A, Risk Factors.” The forward-looking statements in this press release and on the related conference call are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
Wyeth
CONTACT: Media, Douglas Petkus, +1-973-660-5218, or Investors, JustinVictoria, +1-973-660-5340, both of Wyeth
Web site: http://www.wyeth.com/
